Therapy Areas: Oncology
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
14 August 2025 - Nanjing Leads Biolabs Co, Ltd (9887.HK) announced on Thursday that it has completed patient enrollment in its pivotal single-arm registrational trial (CTR20213023) evaluating Opamtist...
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
14 August 2025 - BioDlink, a China-based pharmaceutical company, announced on Wednesday that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia's Na...
Mabwell doses first TNBC patient in Bulumtatug Fuvedotin US clinical study
13 August 2025 - Chinese biopharmaceutical company Mabwell (SH:688062) announced on Tuesday the first patient dosing in the United States for a clinical study of its novel nectin-4-targeting antibody-...
Merck reports positive Phase 3 results for Keytruda and Padcev in muscle-invasive bladder cancer
12 August 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the Phase 3 KEYNOTE-905 trial met its primary and key second...
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis
11 August 2025 - Pharmaceutical development company Nuformix plc (LSE:NFX) declared on Monday that it has submitted an application to the US Food and Drug Administration for Orphan Drug Designation (O...
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
11 August 2025 - Akeso Inc (9926.HK) a China-based pharmaceutical company, announced on Sunday that the first patient has been dosed in its multicentre, randomised, double-blind Phase III study (AK112...